Zhi Dong Pan

Direttore/Membro del Consiglio presso MabPlex International Co., Ltd.

40 anni

Non-Energy Minerals

Health Technology

Consumer Services

Profilo

Zhi Dong Pan is currently a Director at MabPlex International Co., Ltd.
He previously served as a Member-Supervisory Board at Dalian Huarui Heavy Industry Group Co., Ltd.
He earned a doctorate degree from Dalian Maritime University in 2017.

Posizioni attive di Zhi Dong Pan

Società	Posizione	Inizio
MabPlex International Co., Ltd. MabPlex International Co., Ltd. Pharmaceuticals: MajorHealth Technology MabPlex International Co., Ltd. engages in the provision of contract development and manufacturing organization (CDMO) services in the biopharmaceutical field. It provides CDMO services for monoclonal antibodies, double antibodies, polyclonal antibodies, fusion proteins, antibody-drug conjugates, recombinant vaccines, recombinant proteins, and other biological drugs; and cell culture medium. The company was founded by Jan Min Fang on June 25, 2013 and is headquartered in Yantai, China.	Direttore/Membro del Consiglio	01/03/2020

Tutte le posizioni attive di Zhi Dong Pan

Precedenti posizioni note di Zhi Dong Pan

Società	Posizione	Fine
DALIAN HUARUI HEAVY INDUSTRY GROUP CO., LTD.	Direttore/Membro del Consiglio	-

Vedi nel dettaglio l'esperienza di Zhi Dong Pan

Formazione di Zhi Dong Pan

Dalian Maritime University

Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Zhi Dong Pan

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
DALIAN HUARUI HEAVY INDUSTRY GROUP CO., LTD.	Non-Energy Minerals

Aziende private	1
MabPlex International Co., Ltd. MabPlex International Co., Ltd. Pharmaceuticals: MajorHealth Technology MabPlex International Co., Ltd. engages in the provision of contract development and manufacturing organization (CDMO) services in the biopharmaceutical field. It provides CDMO services for monoclonal antibodies, double antibodies, polyclonal antibodies, fusion proteins, antibody-drug conjugates, recombinant vaccines, recombinant proteins, and other biological drugs; and cell culture medium. The company was founded by Jan Min Fang on June 25, 2013 and is headquartered in Yantai, China.	Health Technology